Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 20, 2005. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory notification of share transactions and does not contain financial performance data.
Material Changes
The material change reported is a transfer of 330,122 Ordinary Shares from the GlaxoSmithKline Employee Trust ("the GSK Trust") to participants in the SmithKline Beecham Employee Share Option Plan 1991. This transaction occurred on December 19, 2005, and was advised to the Company on December 20, 2005.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on business strategy, or discussion of risks and contingencies. The transaction is noted as being in accordance with Disclosure Rule 3.1.4R(1)(b). The GSK Trust is identified as a discretionary trust where all employees or former employees of GlaxoSmithKline plc and its subsidiaries are potential beneficiaries.
Key Facts for Investor Verification
- Transaction Date: December 19, 2005.
- Shares Transferred: 330,122 Ordinary Shares.
- Source: Abacus (GSK) Trustees Limited (GSK Trust).
- Destination: Participants in the SmithKline Beecham Employee Share Option Plan 1991.
- Directors with Interest: Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop hold interests in the GSK Trust shares in the same capacity as other employees.